Back to Browse Journals » Infection and Drug Resistance » Volume 1

Procalcitonin implication in renal cell apoptosis induced by acute pyelonephritis in children

Authors Hafid Belhadj-Tahar, Yvon Coulais, Mathieu Tafani, François Bouissou

Published Date August 2008 Volume 2008:1 Pages 17—20

DOI http://dx.doi.org/10.2147/IDR.S3435

Published 12 August 2008

Hafid Belhadj-Tahar1,2, Yvon Coulais2, Mathieu Tafani2, François Bouissou3

1Groupe Santé Recherche, Toulouse, France; 2EA 3033 Université Paul Sabatier III, Toulouse, France; 3Service de Néphrologie Pédiatrique, CHU Purpan, Toulouse, France

Abstract: The aim of this biomedical trial was to clarify the physiological role of procalcitonin (PCT) in renal parenchyma apoptosis and fibrosis caused by acute childhood pyelonephritis. This prospective study enrolled 183 children. All children were treated with bi-therapy according to the French consensus on acute pyelonephritis treatment dated November 16, 1990: intravascular administration of ceftriaxone 50 mg/kg/day and netromicine 7 mg/kg/day during the first 48 hours, followed by specific antibiotherapy suited to antibiogram. On admission, PCT, C-reactive protein, and phospholipase A2 were quantified in serum. Scintigraphy monitoring with 99mTc-DMSA was performed on day 4 and 9 months later, in the presence of persistent abnormalities. On day 4, 78% presented renal parenchyma alterations and 30% renal fibrosis 9 months after admission. Paradoxically, PCT level was significantly lower in the presence of renal fibrosis due to cell apoptosis (4.19 vs 7.59 µgL-1). A significant increase in PCT indicated favorable progress (recovery 7.55 vs aggravation 3.34) and no difference between recovery and improvement. This result suggests the protective effect of PCT against apoptosis by nitric oxide down-regulation.

Keywords: acute pyelonephritis, procalcitonin, apoptosis, fibrosis, technetium-DMSA

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial

Checa MA, Brassesco M, Sastre M, Gómez M, Herrero J, Marque L, Brassesco A, Espinós JJ

International Journal of Women's Health 2015, 7:219-225

Published Date: 12 February 2015

Proliferative effect of Hachimijiogan, a Japanese herbal medicine, in C2C12 skeletal muscle cells

Takeda T, Tsuiji K, Li B, Tadakawa M, Yaegashi N

Clinical Interventions in Aging 2015, 10:445-451

Published Date: 10 February 2015

Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Tao KY, Li XX, Xu WZ, Wang Y, Zhu SM, Xie HX, Luo WH, Xu YJ, Xu XL

OncoTargets and Therapy 2015, 8:147-155

Published Date: 14 January 2015

Patient inclusion in transfusion medicine: current perspectives

Friedman MT, Bizargity P, Gilmore S, Friedman A

International Journal of Clinical Transfusion Medicine 2015, 3:7-16

Published Date: 13 January 2015

Racial differences in tumor necrosis factor-α-induced endothelial microparticles and interleukin-6 production

Brown MD, Feairheller DL, Thakkar S, Veerabhadrappa P, Park JY

Vascular Health and Risk Management 2011, 7:541-550

Published Date: 26 August 2011